ASH 2020: Dr. William Wierda on minimal residual disease (MRD)-guided discontinuation of ibrutinib + venetoclax in chronic lymphocytic leukemia (CLL)
What is MRD Testing? When is it Done? What can it tell us? Find out how Dr. Koffman relied on the results of his post-CAR-T clonoSEQ MRD testing in his decision to stop taking ibrutinib after nearly 8 years.